Literature DB >> 17673924

Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries.

Zhihong Zhang1, Meenakshi Singh, Susan Davidson, Daniel G Rosen, Gong Yang, Jinsong Liu.   

Abstract

The ovarian epithelial cells carrying heterozygous BRCA1 or BRCA2 mutation (we called BRCA1/2 mutation) are known to predispose to the development of ovarian cancer; however, the molecular basis of such predisposition is largely unknown. We hypothesize that BTAK may be a potential target for heterozygous BRCA1/2 mutation. We sought to determine the relationship between the status of BRCA1/2 heterozygous mutation and BTAK expression in prophylactically removed ovaries as compared with normal ovaries and ovarian cancer controls. Western blot analysis of BTAK was performed in a primary cell culture carrying heterozygous BRCA1 mutation and three normal ovarian surface epithelial cell cultures. Immunohistochemical analysis of BTAK expression was also performed by image analysis in ovaries of 21 patients with known BRCA1/2 mutation or very strong family history of breast/ovarian cancer that underwent prophylactic oophorectomy, 38 normal ovaries from patients without any known mutation, and 194 ovarian carcinomas. The BTAK expression was significantly increased in primary culture carrying a heterozygous BRCA1 mutation as compared to those with no known BRCA1/2 mutation. Immunohistochemical staining of BTAK showed increased expression in ovarian epithelial cells carrying BRCA1/2 mutation or strong breast/ovarian family history compared with normal ovaries (P<0.001). Higher BTAK expression was found in ovarian cancer cells compared to ovaries without cancer but with known BRCA1/2 mutation or strong family history (P<0.001), and expression levels of BTAK and p53 were directly correlated (r=0.306; P<0.001). Increased expression of BTAK is directly correlated with mutation status of BRCA1/2 genes, suggesting that mutation in a single allele of either BRCA1 or 2 may be responsible for the activation of BTAK. This activation may be a key early genetic event in the development of hereditary ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673924     DOI: 10.1038/modpathol.3800945

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

Authors:  Yuanhua Cheng; Wei Cui; Quan Chen; Chen-Ho Tung; Mingjuan Ji; Fushi Zhang
Journal:  J Comput Aided Mol Des       Date:  2011-01-11       Impact factor: 3.686

2.  AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Authors:  Fan Yang; Xiaoqing Guo; Gong Yang; Daniel G Rosen; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-03-25       Impact factor: 7.842

3.  Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer.

Authors:  Ji Yun Lee; Huarong Yang; Donghwa Kim; Kay Zin Kyaw; Ruoci Hu; Yanhua Fan; Sang Kook Lee
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-02

4.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

5.  Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines.

Authors:  Cong Wang; Qin Yan; Minmin Hu; Di Qin; Zhenqing Feng
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

6.  Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model.

Authors:  Daniel Winardi; Pei-Yi Chu; Guan-Yu Chen; Ke Wang; Wei-Yu Hsu; Ching-Liang Hsieh; Yung-Hsiang Chen; Yang-Chang Wu; Juan-Cheng Yang
Journal:  Int J Mol Sci       Date:  2022-02-07       Impact factor: 5.923

Review 7.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.